Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

Sponsor
Peking University People's Hospital
Study ID
NCT04213222
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    bevacizumab combined with chemotherapy

Study Details

Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.

Key Dates

First listed
Dec 30, 2019
Start date
Oct 31, 2020
Status verified
Aug 2020
Primary completion
Jun 30, 2022
Completion
Dec 31, 2023

Study Design

Enrollment
300 participants (estimated)

Primary Outcome Measure

estimated ORR [ Time Frame: 6-8 weeks ]

Central Contacts

Related Studies